Drug Profile
Research programme: anticancer IgG antibodies - Adimab/Memorial Sloan Kettering
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Adimab
- Developer Adimab; Memorial Sloan-Kettering Cancer Center
- Class Antibodies; Immunoglobulins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Cancer in USA (Parenteral)